Applying New Halo Standard, the Federal Circuit Reverses Course and Affirms Finding of Willful Infringement

Sep 14, 2016

Reading Time : 1 min

The parties involved in this appeal represent the two main competitors in the orthopedic pulsed lavage device market. In 2010, Stryker sued Zimmer for infringement of three patents. On summary judgment, the district court found that Zimmer infringed two of the three asserted patents. The parties then proceeded to trial on the issue of infringement of the third patent, willfulness of all three patents and Zimmer’s invalidity defenses. Following a jury verdict in which Zimmer was found to willfully infringe all three asserted patents and the patents were found to be not invalid, the district court awarded treble damages to Stryker. The district court also found the case exceptional, awarded fees to Stryker and entered a permanent injunction against Zimmer.

In its initial review, the Federal Circuit reversed the jury’s finding of willfulness. However, the Supreme Court granted certiorari to consider whether the test for willfulness articulated in Seagate was consistent with the Patent Act. In its Halo decision, the Supreme Court described the Seagate test as too restrictive for district courts to exercise their discretion and held that willfulness should be evaluated under a preponderance of the evidence standard. In view of this decision, the Supreme Court vacated the Federal Circuit’s earlier decision in this case. On remand, the Federal Circuit affirmed the jury’s finding that Zimmer willfully infringed Stryker’s patents because the jury made its finding under the clear and convincing evidentiary standard, which exceeds the preponderance of the evidence standard articulated by the Supreme Court in Halo. However, the Federal Circuit vacated the award of enhanced damages and remanded the case to allow the district court the opportunity to “exercise its discretion” and determine whether enhancement is appropriate in view of the circumstances of the case.

Stryker Corporation v. Zimmer, Inc., No. 2013-1668 (Fed. Cir. September 12, 2016).

 

Share This Insight

Previous Entries

IP Newsflash

October 31, 2025

The District Court for the Northern District of California recently granted a defendant’s motion to bifurcate, ordering that issues related to PGR estoppel should be decided in a bench trial, while the remaining issues in the case should proceed to a jury trial.

...

Read More

IP Newsflash

October 31, 2025

The Northern District of Iowa recently held that a defendant’s motion for partial summary judgment of invalidity was barred after the PTAB issued final written decisions, regardless of when the motion was filed. The defendant filed its motion before the final written decisions were issued, but the court rejected the defendant’s argument that the timing of the motion insulated it from estoppel.

...

Read More

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

IP Newsflash

September 17, 2025

A magistrate judge in the District of Delaware issued a Report and Recommendation, that found the sole asserted claim was a “single means” claim and therefore invalid for lack of enablement. In reaching that conclusion, the magistrate judge rejected the patentee’s argument that the preamble of the claim disclosed a second element that satisfied the combination requirement of Section 112, paragraph 6 because the preamble simply recited a descriptor of the very apparatus that was the subject of the means-plus-function limitation in the body of the claim. The district court judge presiding over this case has scheduled a hearing to review the magistrate’s ruling.

...

Read More

IP Newsflash

September 9, 2025

The Federal Circuit has affirmed the PTAB’s determination that a patent challenger did not show the challenged claims were unpatentable for obviousness. The Federal Circuit concluded that substantial evidence, which included expert testimony, showed there was no motivation to combine the references.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.